Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,828 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted deletion of Kcne3 impairs skeletal muscle function in mice.
King EC, Patel V, Anand M, Zhao X, Crump SM, Hu Z, Weisleder N, Abbott GW. King EC, et al. Among authors: patel v. FASEB J. 2017 Jul;31(7):2937-2947. doi: 10.1096/fj.201600965RR. Epub 2017 Mar 29. FASEB J. 2017. PMID: 28356343 Free PMC article.
KCNE3 (MiRP2) forms heteromeric voltage-gated K(+) channels with the skeletal muscle-expressed KCNC4 (K(v)3.4) alpha subunit. KCNE3 was the first reported skeletal muscle K(+) channel disease gene, but the requirement for KCNE3 in skeletal muscle has been questioned. ...Th …
KCNE3 (MiRP2) forms heteromeric voltage-gated K(+) channels with the skeletal muscle-expressed KCNC4 (K(v)3.4) alpha subunit. KCNE3 w …
Utility of scores to predict alcohol use after liver transplant (lt): take them with a grain of salt.
Houston K, Duong N, Sterling RK, Asgharpour A, Bullock S, Weinland S, Keller N, Smirnova E, Khan H, Matherly S, Wedd J, Lee H, Siddiqui M, Patel V, Arias A, Kumaran V, Lee S, Sharma A, Khan A, Imai D, Levy M, Bruno D. Houston K, et al. Among authors: patel v. Liver Transpl. 2024 May 23. doi: 10.1097/LVT.0000000000000407. Online ahead of print. Liver Transpl. 2024. PMID: 38775570
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell B, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921-8. Online ahead of print. Lancet. 2024. PMID: 38768626
5,828 results